CING News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CI

Mkt Cap

$63.9M

Volume

224.05K

Next Earnings

November 12th

Loading chart

CI

CINGCingulate Inc. Common Stock

CING

Pay with—

Available Balance0.00

CI

Mkt Cap

$63.8M

Volume

224.05K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Cingulate Provides Management Team UpdateCingulate Inc. placed CEO Shane J. Schaffer on administrative leave due to unrelated legal matters. Jennifer Callahan was appointed interim CEO, retaining her CFO role, while board member Jay Roberts became Executive Chairman to ensure business continuity.GlobeNewswire Inc. · Aug 15, 2025

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial OfficerAllarity Therapeutics announced the appointment of Jeff Ervin as its new Chief Financial Officer, succeeding Alexander Epshinsky. Ervin brings nearly two decades of executive leadership experience in healthcare and biotech sectors, and will support the company's clinical development of stenoparib, a cancer treatment drug.GlobeNewswire Inc. · Jul 7, 2025

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones AchievedCingulate Inc. reported positive results for its lead ADHD asset CTx-1301, including successful completion of Phase 3 trials and plans to submit a New Drug Application in mid-2025. The company also strengthened its balance sheet through various financing activities.GlobeNewswire Inc. · Mar 26, 2025

Cingulate Announces Adjournment of Special MeetingCingulate Inc. has adjourned its Special Meeting of Stockholders to provide additional time for stockholders to vote on all proposals. The company's Board of Directors continues to believe that the proposals are in the best interests of the stockholders.GlobeNewswire Inc. · Aug 23, 2024

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHDCingulate Inc. announced that it was issued a European patent for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The patent will cover up to 30 European territories, including the United Kingdom.GlobeNewswire Inc. · Aug 15, 2024

Why WD-40 Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - BenzingaWD-40 Company reported stronger-than-expected Q3 results, leading to a 12.5% jump in its stock price in pre-market trading. Several other stocks also saw significant price movements in the pre-market session.Benzinga · Jul 11, 2024

Cingulate Announces Exercise of Warrants for $1.86 Million Gross ProceedsKANSAS CITY, Kan., June 28, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (the “Company”) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the entry into definitive agreements for the immediate exercise of certain outstanding Series A warrants to purchase up to an aggregate of 2,125,000 shares of common stock of the Company and Series B warrants to purchase up to an aggregate of 1,062,500 shares of common stock of the Company originally issued in February 2023, having an exercise price of $2.00 per share, at a reduced exercise price of $0.585 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-276502). The offering is expected to close on or about July 1, 2024, subject to satisfaction of customary closing conditions.GlobeNewswire Inc. · Jun 28, 2024

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access EventKANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, and preeminent board-certified psychiatrist and Cingulate scientific advisor Dr. Ann Childress, MD, will participate in a live Benzinga All Access event on June 26, 2024, at 10:30 a.m. CST.GlobeNewswire Inc. · Jun 25, 2024

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing ClearanceTwelve Required Registration Batches CompletedNew Drug Application Being Prepped for SubmissionGlobeNewswire Inc. · Jun 25, 2024

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live AccessKANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that longstanding Cingulate investor and board member Peter J. Werth will join Cingulate Chairman and CEO Shane J. Schaffer in a live Benzinga All Access event on Friday May 3, 2024, at 12:10 p.m. EST.GlobeNewswire Inc. · Apr 30, 2024

to start trading

CI

CINGCingulate Inc. Common Stock

CING

Pay with—

Available Balance0.00

Your PositionYou don't own any CING yet.

Related Tickers

Earnings